AtaiBeckley (ATAI) Net Income towards Common Stockholders (2020 - 2026)

AtaiBeckley's (ATAI) quarterly Net Income towards Common Stockholders came in at -$61.1 million in Q3 2025, down 132.34% year-on-year from $188.8 million in Q3 2024, and down 120.25% quarter-over-quarter from -$27.7 million in Q2 2025.

AtaiBeckley (ATAI) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

AtaiBeckley's Net Income towards Common Stockholders history runs 2 years deep, the most recent figure standing at -$29.8 million for Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders fell 12.68% year-over-year to -$29.8 million; the TTM figure through Mar 2026 stood at -$56.2 million (changed N/A YoY), while the FY2025 annual figure was -$660.0 million, down 342.19% from the prior year.
  • Net Income towards Common Stockholders came in at -$61.1 million for Q3 2025 at AtaiBeckley, down from -$27.7 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$26.4 million in Q1 2025 to a low of -$29.8 million in Q1 2026.
  • The 5-year median for Net Income towards Common Stockholders is -$33.1 million (2023), against an average of -$31.1 million.
  • Across the five-year window, Net Income towards Common Stockholders slumped 1190.93% in 2022 and surged 230.56% in 2023, its largest moves.
  • AtaiBeckley's Net Income towards Common Stockholders stood at -$52.1 million in 2021, then advanced by 13.67% to -$45.0 million in 2022, then surged by 59.36% to -$18.3 million in 2023, then sank by 112.98% to -$39.0 million in 2024, then plunged by 56.77% to -$61.1 million in 2025.
  • The last three Net Income towards Common Stockholders figures came in at -$61.1 million (Q3 2025), -$27.7 million (Q2 2025), and -$26.4 million (Q1 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -13.56 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 2.50 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.63 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 AtaiBeckley 1.45 Bn 1.45 Bn - -29.78 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -29.78 Mn
Sep 30, 2025 -61.07 Mn
Jun 30, 2025 -27.73 Mn
Mar 31, 2025 -26.43 Mn
Mar 31, 2025 -26.43 Mn
Dec 31, 2024 -38.96 Mn
Sep 30, 2024 -26.29 Mn
Jun 30, 2024 -57.31 Mn
Mar 31, 2024 -26.71 Mn
Dec 31, 2023 -18.29 Mn
Sep 30, 2023 44.24 Mn
Jun 30, 2023 -33.04 Mn
Mar 31, 2023 -33.14 Mn
Dec 31, 2022 -45.01 Mn
Sep 30, 2022 -33.89 Mn
Jun 30, 2022 -36.62 Mn
Mar 31, 2022 -36.87 Mn
Dec 31, 2021 -52.14 Mn
Sep 30, 2021 -31.16 Mn
Jun 30, 2021 -48.46 Mn